Cumulative Response to Guselkumab Through Week 24 of Induction in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study

被引：0

作者：

Rubin, David T. ^{[1
]}

Sands, Bruce E. ^{[2
]}

Lichtenstein, Gary R. ^{[3
]}

Baker, Thomas ^{[4
]}

Huang, Kuan-Hsiang G. ^{[4
]}

Germinaro, Matthew ^{[4
]}

Miao, Ye ^{[4
]}

Zhang, Hongyan ^{[4
]}

Nancey, Stephane ^{[5
]}

Allegretti, Jessica R. ^{[6
]}

Feagan, Brian G. ^{[7
]}

Hisamatsu, Tadakazu ^{[8
]}

Panes, Julian ^{[9
]}

Dignass, Axel ^{[10
]}

Bressler, Brian ^{[11
]}

Peyrin-Biroulet, Laurent ^{[12
,13
]}

机构：

[1] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA

[2] Icahn Sch Med Mt Sinai, New York, NY USA

[3] Univ Penn, Philadelphia, PA USA

[4] Janssen Res & Dev LLC, Spring House, PA USA

[5] Hosp Civils Lyon, Hop Lyon Sud, Pierre Benite, Auvergne, France

[6] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA

[7] Western Univ, London, ON, Canada

[8] Kyorin Univ, Sch Med, Tokyo, Japan

[9] Hosp Clin Barcelona, Inst Invest Biomed August Pi i Sunyer, Ctr Invest Biomedica Red Enfermedades, Barcelona, Catalonia, Spain

[10] Goethe Univ, Agaples Markus Hosp, Frankfurt, Germany

[11] St Pauls Hosp, Vancouver, BC, Canada

[12] Lorraine Univ, Last Inserm U954, Vandoeuvre Les Nancy, Lorraine, France

[13] Lorraine Univ, CHU Nancy, Vandoeuvre Les Nancy, Lorraine, France

来源：

AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

S903

引用

页码：S672 / S673

页数：2

共 50 条

[31] Efficacy and Safety of Subcutaneous Guselkumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 48 From the Phase 3 GRAVITI Study
Panaccione, Remo
Hart, Ailsa
Steinwurz, Flavio
Danese, Silvio
Hisamatsu, Tadakazu
Cao, Qian
Olurinde, Mobolaji
Vetter, Marion
Yang, Zijiang
Wang, Yuhua
Johanns, Jewel
Terry, Natalie A.
Sands, Bruce E.
D'Haens, Geert R.
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S740 - S741
[32] Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial
Sandborn, W. J.
Ferrante, M.
Bhandari, B. R.
Berliba, E.
Hibi, T.
D'Haens, G. Geert R.
Tuttle, J.
Krueger, K.
Friedrich, S.
Durante, M.
Arora, V.
Feagan, B.
JOURNAL OF CROHNS & COLITIS, 2019, 13 : S54 - S54
[33] Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study
Danese, S.
Vermeire, S.
Zhou, W.
Pangan, A.
Siffledeen, J.
Hebuterne, X.
Nakase, H.
Higgins, P.
Chen, M. H.
Sanchez-Gonzalez, Y.
Huang, B.
Xie, W.
Liu, J.
Weinreich, M.
Pannaccione, R.
JOURNAL OF CROHNS & COLITIS, 2021, 15 : S022 - S024
[34] Efficacy and Safety of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 U-ACHIEVE Study
Danese, Silvio
Vermeire, Severine
Zhou, Wen
Pangan, Aileen
Siffledeen, Jesse
Hebuterne, Xavier
Nakase, Hiroshi
Chen, Minhu
Higgins, Peter
Sanchez-Gonzalez, Yuri
Huang, Bidan
Xian, Wangang
Liu, Jianzhong
Weinreich, Michael
Panaccione, Remo
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S312 - S313
[35] Efficacy and Safety of Upadacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Phase 3 U-ACCOMPLISH Study
Vermeire, Severine
Danese, Silvio
Zhou, Wen
Pangan, Aileen
Greenbloom, Susan
D'Haens, Geert
Panes, Julian
Juillerat, Pascal
Lindsay, James
Loftus, Edward V.
Sandborn, William
Reinisch, Walter
Sanchez-Gonzalez, Yuri
Huang, Bidan
Xian, Wangang
Liu, Jianzhong
Weinreich, Michael
Panaccione, Remo
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S357 - S357
[36] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active ulcerative colitis: Results from the Phase 3 LUCENT-1 study
Andrews, J. M.
D'Haens, G.
Kobayashi, T.
Morris, N.
Lissoos, T.
Hoover, A.
Li, X.
Arora, V.
Milch, C.
Sandborn, W. J.
Sands, B. E.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 132 - 133
[37] Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study
D'Haens, G.
Kobayashi, T.
Morris, N.
Lissoos, T.
Hoover, A.
Li, X.
Arora, V.
Milch, C.
Sandborn, W. J.
Sands, B. E.
JOURNAL OF CROHNS & COLITIS, 2022, 16 : I028 - I029
[38] Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study
Vermeire, S.
Danese, S.
Zhou, W.
Pangan, A.
Greenbloom, S.
D'Haens, G.
Panes, J.
Juillerat, P.
Lindsay, J. O.
Loftus, E. V., Jr.
Sandborn, W. J.
Reinisch, W.
Gonzalez, Y. Sanchez
Huang, B.
Xie, W.
Liu, J.
Weinreich, M. A.
Panaccione, R.
JOURNAL OF CROHNS & COLITIS, 2021, 15 : S021 - S022
[39] EFFICACY AND SAFETY OF MIRIKIZUMAB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 LUCENT-1 STUDY
D'Haens, Geert
Kobayashi, Taku
Morris, Nathan
Lissoos, Trevor
Hoover, Amy
Li, Xingyuan
Arora, Vipin
Milch, Catherine
Sandborn, William J.
Sands, Bruce E.
GASTROENTEROLOGY, 2022, 162 (07) : S214 - S214
[40] Efficacy and Safety of Guselkumab Maintenance Therapy Among Guselkumab Induction Week 24 Clinical Responders: Results From the Phase 3 QUASAR Maintenance Study
Rubin, David T.
Dignass, Axel
Allegretti, Jessica R.
Yarandi, Shadi
Huang, Kuan-Hsiang G.
Germinaro, Matthew
Zhan, Jia
Zhang, Hongyan
Rayyan, Yaser
Saruta, Masayuki
Balderramo, Domingo
Bressler, Brian
Peyrin-Biroulet, Laurent
Hisamatsu, Tadakazu
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S744 - S745

← 1 2 3 4 5 →